Proteomics in Psoriasis: Recent Advances

Overview

Journal In Vivo

Specialty Oncology

Date 2024 Apr 30

PMID 38688625

Authors

Georgios Leotsakos

Ioannis Katafigiotis

Ioannis Leotsakos

Fiori Kousta

Aristeidis Molympakis

Aikaterini Perimeni

Michael Koutsilieris

Affiliations

Soon will be listed here.

Abstract

Psoriasis continues to affect a large percentage of patients worldwide and strongly appears to be a systematic disease. Efforts are being made to understand its etiology, which have led to research extended to genomic analysis with a focus on the role of pro-inflammatory cytokines, which play a major role in the pathogenesis of the disease. Plasma proteomic analysis in various diseases has provided promising results for choosing the right treatment for psoriasis, suggesting that it could play a key role in the prevention, prognosis, and treatment of the disease by individualizing treatment choices based on the proteomic profile of each patient. In this review, we focus on existing data in the bibliography on proteomic analysis in psoriasis and relevant approaches to future targeted therapies.

References

Gschwandtner M, Paulitschke V, Mildner M, Brunner P, Hacker S, Eisenwort G . Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells. Allergy. 2016; 72(1):85-97. DOI: 10.1111/all.12919. View

Feldman S . Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 2019; 82(1):256-257. DOI: 10.1016/j.jaad.2018.07.059. View

Allen M, Ameen H, Veal C, Evans J, Ramrakha-Jones V, Marsland A . The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol. 2005; 124(1):103-6. DOI: 10.1111/j.0022-202X.2004.23511.x. View

Kolbinger F, Loesche C, Valentin M, Jiang X, Cheng Y, Jarvis P . β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2016; 139(3):923-932.e8. DOI: 10.1016/j.jaci.2016.06.038. View

Bonnekoh B, Pommer A, Bockelmann R, Hofmeister H, Philipsen L, Gollnick H . Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment. Skin Pharmacol Physiol. 2007; 20(5):237-52. DOI: 10.1159/000104422. View

Lundberg K, Fritz Y, Johnston A, Foster A, Baliwag J, Gudjonsson J . Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans. Mol Cell Proteomics. 2014; 14(1):109-19. PMC: 4288247. DOI: 10.1074/mcp.M114.042242. View

Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth T, Gottlieb A . Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995; 1(5):442-7. DOI: 10.1038/nm0595-442. View

Sotiropoulou P, Blanpain C . Development and homeostasis of the skin epidermis. Cold Spring Harb Perspect Biol. 2012; 4(7):a008383. PMC: 3385954. DOI: 10.1101/cshperspect.a008383. View

Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y . In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019; 9(9):2475-2488. PMC: 6526001. DOI: 10.7150/thno.31144. View

10.

Anderson N, Anderson N . The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11):845-67. DOI: 10.1074/mcp.r200007-mcp200. View

11.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

12.

Czarnecka A, Zablotna M, Purzycka-Bohdan D, Nowicki R, Szczerkowska-Dobosz A . An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis. Medicina (Kaunas). 2023; 59(11). PMC: 10673501. DOI: 10.3390/medicina59112006. View

13.

Hahn M, Frey S, Hueber A . The novel interleukin-1 cytokine family members in inflammatory diseases. Curr Opin Rheumatol. 2016; 29(2):208-213. DOI: 10.1097/BOR.0000000000000361. View

14.

Li W, Han J, Chan A, Qureshi A . Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2012; 72(7):1200-5. PMC: 3547138. DOI: 10.1136/annrheumdis-2012-202143. View

15.

Gegotek A, Domingues P, Wronski A, Wojcik P, Skrzydlewska E . Proteomic plasma profile of psoriatic patients. J Pharm Biomed Anal. 2018; 155:185-193. DOI: 10.1016/j.jpba.2018.03.068. View

16.

Baliwag J, Barnes D, Johnston A . Cytokines in psoriasis. Cytokine. 2015; 73(2):342-50. PMC: 4437803. DOI: 10.1016/j.cyto.2014.12.014. View

17.

Nair R, Stuart P, Nistor I, Hiremagalore R, Chia N, Jenisch S . Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006; 78(5):827-851. PMC: 1474031. DOI: 10.1086/503821. View

18.

REED W, BECKER S, Rohde R, HEISKELL C . Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol. 1961; 83:541-8. DOI: 10.1001/archderm.1961.01580100005001. View

19.

Plavina T, Wakshull E, Hancock W, Hincapie M . Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J Proteome Res. 2007; 6(2):662-71. DOI: 10.1021/pr060413k. View

20.

Reindl J, Pesek J, Kruger T, Wendler S, Nemitz S, Muckova P . Proteomic biomarkers for psoriasis and psoriasis arthritis. J Proteomics. 2016; 140:55-61. DOI: 10.1016/j.jprot.2016.03.040. View